Clinical trials: Esophagogastric Junction Disorder
Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma
Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial
This study is to evaluate the efficacy and safety of domestic programmed death 1（ PD-1） antibody (Camrelizumab for injection) combined with fluorouracil plus leucovorin, oxaliplatin, and albumin bound paclitaxel (Nab-POF) regimen…
- Conditions
- Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT04510064
- Testing
- Camrelizumab plus mFLOT regimen, R0 surgery
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Metastatic Cancer, Melanoma
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer
- Conditions
- Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- ConsortiumIO (NCT04208958)
- Testing
- VE800, Nivolumab, Vancomycin Oral Capsule
- Where
- 18 sites in United States
- Volunteers
- 56 people
- Sponsor
- Vedanta Biosciences, Inc.
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
MSI-H, PD-1 Immunotherapy
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
Approximately 5% to 10% of gastric cancers have MSI-H/dMMR. According to the results of retrospective analysis of CLASSIC and MAGIC, MSI-H/dMMR was a good prognosis and potential negative predictor of adjuvant chemotherapy for…
- Conditions
- MSI-H, PD-1 Immunotherapy, Gastric Cancer, Adjuvant Therapy
- Trial name
- NCT05468138
- Testing
- SOX, XELOX, PD-1 antibody
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Fudan University
Advanced Solid Tumor, Gastric Cancer
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05159440
- Testing
- TORL-2-307-MAB
- Where
- 8 sites in United States, South Korea
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
Gastric Cancer
S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients
The purpose of this study is to evaluate the effectiveness and safety of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Gastric Adenocarcinoma or Gastroesophageal Junction…
- Trial name
- NCT01824459
- Testing
- S-1, Oxaliplatin, Cisplatin
- Where
- China
- Volunteers
- 576 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction
The purpose of this study is to investigate whether Taxanes or Platinum Plus Capecitabine With Capecitabine Maintenance Treatment as 1st line treatment in he advanced gastric cancer is effective and safe.
- Trial name
- NCT01468389
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Esophageal Cancer, Gastric Cancer
Spanish Registry of Esophagogastric Cancer
This study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the AGAMENON - SEOM group that guarantees a rigorous collection, exploitation and…
- Trial name
- AGAMENON (NCT04958720)
- Testing
- Surgery, Chemotherapy, anti-targeted agents and immunotherapy, Radiotherapy
- Where
- 38 sites in Spain
- Volunteers
- 10,000 people
- Sponsor
- Fundación Sociedad Española de Oncologia Médica
Advanced Gastric Cancer, Advanced Cancer of the Esophagogastric Junction
Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction
Patients with advanced gastric cancer are treated with a combination of RAD001 (everolimus) and Mitomycin C.
- Trial name
- S387 (NCT01042782)
- Testing
- RAD001 and MitomycinC
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Krankenhaus Nordwest
Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus
- Conditions
- Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
- Trial name
- NCT01183559
- Testing
- Vandetanib, 5 Fluorouracil (FU), Carboplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Cancer, Gastric Cancer
Non-Invasive Detection of claudin18.2 in Pancreatic and Gastric/Gastroesophageal Junction Cancer by [68Ga]Ga-NODAGA-SNA014 PET Imaging
The purpose of this study is to use Claudin 18.2 (CLDN18.2)-targeted positron emission tomography (PET) imaging technology to evaluate its detection efficacy and diagnostic threshold for CLDN18.2-positive pancreatic cancer and…
- Conditions
- Pancreatic Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT07554742
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Ruijin Hospital
Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer
Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01360086
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 2 sites in France
- Volunteers
- 65 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Stomach Neoplasms
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
This was a single-arm, prospective study to investigate the efficacy and safety of fruquintinib combined with sintilimab in the second-line treatment of Chinese patients with advanced gastric/GEJ adenocarcinoma.
- Trial name
- NCT05625737
- Testing
- Fruquintinib, Sintilimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastroesophageal Junction Adenocarcinoma, Stomach Adenocarcinoma
Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
This study aims to evaluate the efficacy and safety of Sintilimab plus CAPOX in the conversion therapy for patients with unresectable locally advanced or limited metastatic adenocarcinoma of the stomach or esophagogastric junction
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Stomach Adenocarcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer
- Trial name
- CTSCAPOXSEA (NCT04263870)
- Testing
- sintilimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sichuan University
Cancer of Esophagus, Esophagogastric Junction Disorder
CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1
This is an exploratory observational biomarker study in approximately 100 eligible patients with resectable adenocarcinomas of the esophagus and gastro- esophageal junction (GEJ) type I-II (GEAC) to investigate the difference…
- Trial name
- CIRCULATE1 (NCT04455282)
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.
- Conditions
- Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06251973
- Testing
- AgenT-797, Botensilimab, Balstilimab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stomach Neoplasms, Neoplasms Metastasis
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Patients with inoperable, locally advanced or recurrent and/or HER2-positive metastatic gastric or gastro-esophageal junction cancer, with no prior treatment for metastatic disease are to be recruited in the study.
- Conditions
- Stomach Neoplasms, Neoplasms Metastasis, ERBB2 Gene Amplification
- Trial name
- NCT02004769
- Testing
- Trastuzumab, Docetaxel, Capecitabine
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer, Gastroesophageal Cancer
Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma
The combination of cisplatin and irinotecan has significant anti-tumor activity in esophageal cancer. Oxaliplatin has been shown to have activity in combination with 5-Fluorouracil (5FU) and radiation in treatment of locally…
- Trial name
- NCT00256269
- Testing
- Oxaliplatin, Irinotecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, Irvine
Stomach Neoplasms, Surgery
Quantitative Fluorescent Guided Robotic Surgery for Cancer of the Gastroesophageal Junction
The investigators also aim to use our previously described quantifying method (q-ICG), to evaluate changes in gastric perfusion, during resection of cancer in the gastroesophageal junction (GEJ) and if a change in the operative…
- Trial name
- NCT04107623
- Testing
- Indocyanine Green
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00891878
- Testing
- capecitabine, sunitinib malate
- Where
- 182 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alliance for Clinical Trials in Oncology